Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 5/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11896989 | 1.00 | NPC1 (0.41) | NPC1RAB9ACYP3A4NPY5RIL1B | |
| SCHEMBL15229464 | 0.88 | IL1B (0.45) | NPC1RAB9ANPY5RIL1B | |
| SCHEMBL16530785 | 0.84 | IDH1 (0.34) | — | |
| SCHEMBL16530784 | 0.84 | IDH1 (0.34) | — | |
| SCHEMBL18250667 | 0.81 | CCNT1 (0.31) | — | |
| SCHEMBL22761841 | 0.81 | IL1B (0.53) | NPC1RAB9AIL1B | |
| SCHEMBL11897136 | 0.81 | ADRA2A (0.37) | — | |
| SCHEMBL934703 | 0.81 | ADRA2A (0.37) | — | |
| SCHEMBL23963612 | 0.78 | NPC1 (0.43) | NPC1RAB9ACYP3A4NPY5R | |
| SCHEMBL296168 | 0.77 | IL1B (0.41) | NPC1RAB9AIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9498478-B2 | Spiro aminic compounds with NK1 antagonist activity | ROTTAPHARM BIOTECH S.R.L. (IT) | 2016-11-22 | — | — | US | disclosed |
| US-20160045500-A1 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY | Rottapharm Biotech Srl (IT) | 2016-02-18 | — | — | US | disclosed |
| EP-2670745-B1 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY | Rottapharm Biotech Srl (IT) | 2015-11-04 | — | — | EP | disclosed |
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| EP-2670745-A1 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY | Rottapharm S.p.A. (IT) | 2013-12-11 | — | — | EP | disclosed |
| US-20130310400-A1 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY | ROTTAPHARM S.P.A. (IT) | 2013-11-21 | — | — | US | disclosed |
| WO-2012104338-A1 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY | ROTTAPHARM S.P.A. (IT) | 2012-08-09 | — | — | WO | disclosed |
| EP-2484674-A1 | Spiro aminic compounds with NK1 antagonist activity | ROTTAPHARM S.P.A. (IT) | 2012-08-08 | — | — | EP | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
| EP-2275421-A1 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | Rottapharm S.p.A. (IT) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310400-A1 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY | TACR2, TACR1, TAC3 | NPC1 671/4885RAB9A 3105/4885CYP3A4 1936/4885 |
| US-20160045500-A1 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY | TACR2, TACR1, TAC3 | NPC1 671/4885RAB9A 3105/4885CYP3A4 1936/4885 |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | NPC1 465/4885RAB9A 1184/4885CYP3A4 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.